|
IQVIA™ Real-World Insights Bibliography
| Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy |
| Author(s): Colombo GL, Heiman F, Peduto I |
| Affiliations(s): Colombo GL: CEFAT - Department of Drug Sciences, University of Pavia, Pavia, Italy. Peduto I, Heiman F: IQVIA Solutions Italy S.r.l., Milan, Italy, |
Publication(s): Ther Clin Risk Manag. 2021 Apr 21;17:345-356. doi: 10.2147/TCRM.S301005
|
| Document Type(s): Article, |
| Countries: Italy, |
| Click here for the abstract |
C:
Y: |
Health economics, Overactive bladder,
2021 |
|
L:
A: |
English
Clinical setting: Primary care, Cost of illness, |
|
 |
| |
| |
| Impact of overactive bladder symptoms on work activity: the ACTIVHA study |
| Author(s): Rapariz M1, Mora AM2, Roset M3. |
| Affiliations(s): 1, Servicio de Urología, Hospital de Gran Canaria Dr. Negrín, Gran Canaria, España
2,Astellas Pharma, Madrid, España
3, Real World Insights, QuintilesIMS, Barcelona, España |
| Publication(s): |
| Document Type(s): |
| Countries: |
C:
Y: |
Overactive bladder,
2018 |
|
L:
A: |
Spanish
|
|
|
| |
| |
| The Economic Impact of Overactive Bladder Syndrome in Six Western Countries. |
| Author(s): Irwin DE1, Mungapen L2, Milsom I3, Kopp Z4, Reeves P2, Kelleher C5 |
| Affiliations(s): 1Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, US 2 IMS Health incorporating Fourth Hurdle Consulting Ltd, London, UK 3 Department of Obstetrics & Gynaecology, Sahlgrenska Academy at the University of Gothenburg, Sweden 4 Pfizer Inc., New York, USA, , 5 Department of Obstetrics and Gynaecology, Guy?s and St Thomas? NHS Foundation Trust, London, UK |
Publication(s): British Journal of Urology International (BJU International), 103(2):202-209
|
| Document Type(s): Article, |
| Countries: Canada, Germany, Italy, Spain, Sweden, UK, |
| Click here for the abstract |
C:
Y: |
Overactive bladder,
2009 |
|
L:
A: |
English
Budget impact, |
|
|
| |
| |
| The Toviaz YourWay Plan: A multidimensional program for managing overactive bladder. |
| Author(s): Taylor P1, Trocio J2, Schabert VF3, Golberg EL3, Bavendam T2, Brubaker L4 |
| Affiliations(s): 1 Emory University, Atlanta, GA, USA 2 Pfizer Inc., New York, NY, USA 3 IMS Health, Inc., Falls Church, VA, USA 4 Loyola University, Maywood, IL, USA |
Publication(s): American Urogynecologic Society 30th Annual Scientific Meeting, 2009, September, Hollywood, FL, USA
|
| Document Type(s): Oral presentation, |
| Countries: |
C:
Y: |
Overactive bladder,
2009 |
|
L:
A: |
English
Review, |
|
|
| |
| |
| Challenges for managing overactive bladder and guidance for patient support. |
| Author(s): Schabert VF1, Bavendam T2, GoldbergEL1, Trocio JN2, Brubaker L3 |
| Affiliations(s): 1 IMS Health, Inc., Falls Church, VA, USA 2 Pfizer, Inc., New York, NY, USA 3 Loyola University, Chicago, IL, USA |
Publication(s): American Journal of Managed Care, 2009, 15(4 Suppl): S118-122
|
| Document Type(s): Article, |
| Countries: |
C:
Y: |
Overactive bladder,
2009 |
|
L:
A: |
English
Survey research, |
|
|
| |
| |
| Dvelopment of a multidimensional approach to managing overactive bladder. |
| Author(s): Taylor P1, Goldberg EL2, Schabert VF2, Trocio J3, Bavendam T3 |
| Affiliations(s): 1 Emory University, Atlanta, GA, USA 2 IMS Health, Inc., Falls Church, VA, USA 3 Pfizer Inc., New York, NY, USA |
Publication(s): American Academy of Physician Assistants 37th Annual Conference, 2009, May 23-28, San Diego, CA, USA
|
| Document Type(s): Poster, |
| Countries: |
C:
Y: |
Overactive bladder,
2009 |
|
L:
A: |
English
Survey research, |
|
|
| |
| |
| Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. |
| Author(s): Pelletier EM1, Vats V2, Clemens JQ3 |
| Affiliations(s): 1IMS Health, Watertown, MA, USA, 2Pfizer Inc., New York, NY, USA, 3University of Michigan, Ann Arbor, MI, USA |
Publication(s): American Journal of Managed Care, 2009, 15(Suppl 4): S108-S114
|
| Document Type(s): Manuscript in preparation, |
| Countries: USA, |
C:
Y: |
Overactive bladder,
2009 |
|
L:
A: |
English
Compliance, Cost analysis, |
|
|
| |
| |
| Patterns and Predictors of Overactive Bladder-specific Quality of Life. |
| Author(s): Benner J1, Brubaker L, Bavendam T, Fanning F, Goldberg E2, Trocio J3, Jumadilova Z
|
| Affiliations(s): 1 Formerly of IMS Health, Falls Church, VA, US 2 IMS Health, Falls Church, VA 3 Pfizer, New York, NY, US |
Publication(s): Journal of Pelvic Medicine & Surgery;2007 Sept/Oct;13(5):302-303(#91P)
|
| Document Type(s): Manuscript in preparation, |
| Countries: USA, |
C:
Y: |
Overactive bladder,
2008 |
|
L:
A: |
English
Quality of life, |
|
|
| |
| |
| ?Overactive bladder symptom bother is more prevalent in men than women at older ages.? |
| Author(s): Albo M, Rovner E, Mullins C, Becker R, Jumadilova Z, Benner J. |
| Affiliations(s): |
Publication(s): American Urology Association Western Section Meeting, October 2006
|
| Document Type(s): Oral presentation, |
| Countries: USA, |
C:
Y: |
Overactive bladder,
2006 |
|
L:
A: |
English
Epidemiological study, |
|
|
| |
| |
| ?Patient-Reported Reasons for Discontinuing Overactive Bladder (OAB) Medications.? |
| Author(s): Brubaker L, Nichol M, Fanning T, Becker R, Jumadilova Z, Benner J |
| Affiliations(s): |
Publication(s): Annual International Continence Society Meeting, November 2006.
|
| Document Type(s): Abstract, |
| Countries: USA, |
C:
Y: |
Overactive bladder,
2006 |
|
L:
A: |
English
|
|
|
| |
| |
 1 of 2 
|
|
